Replimune Group's stock dropped about 84% between October 2025 and April 2026 after the FDA rejected its RP1 biologics license application due to unresolved study design concerns. Despite company statements suggesting progress toward approval, the FDA's complete response letter in April 2026 revealed that critical issues remained unaddressed, causing a sharp decline in share price. A securities class action lawsuit has been filed alleging the company misled investors about the drug's regulatory status. Investors who bought shares during this period may seek compensation by October 5, 2026.
Replimune Group's stock faced a severe decline of about 84% between October 2025 and April 2026 following regulatory setbacks. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: out of 91 priced US health-sector stocks, 59 rose and 31 fell. Notable movers include Recursion Pharmaceuticals Inc (RXRX) with a price of USD 3.37 and a 1-day change of +5.64%, Illumina, Inc. (ILMN) at USD 241.64 with a 1-day change of +5.55%, and Ginkgo Bioworks Holdings Inc (DNA) at USD 7.44 with a 1-day change of +5.38%.
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
DNO ASA announced that its offer to acquire Capricorn Energy plc has lapsed as of November 9, 2026. This means the acquisition attempt will not proceed, impacting DNO's expansion plans in the oil and gas sector. Investors should monitor DNO's next st...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
Juniper Research forecasts that losses from fraudulent robocalls in North America will decrease by 33%, from $18.4 billion in 2026 to $12.3 billion in 2031. This decline is attributed to telecom operators adopting advanced fraud prevention technologi...
Direxion Daily Semiconductor Bull 3X ETF (SOXL) has declined 83% since June 2026, underperforming major indexes like SOXX, QQQ, and SPY. The ETF is considered highly volatile and risky, unsuitable for long-term investors, with potential for further l...
